PBG BioPharma Inc. announces its lead drug candidate ProZ001 is being used in a groundbreaking phase II, randomized, double-blind, placebo-controlled, cross-over trial as a potential treatment for symptoms associated with Alzheimer’s disease.
Edmonton, Canada, 11 April 2024 – PBG BioPharma Inc. (PBG) a leading biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, announces its lead cannabinoid drug (ProZ001) is being used in a phase II, randomized, double-blind, placebo-controlled, cross-over trial, aimed at addressing symptoms of Alzheimer’s disease. The trial is being conducted by research teams, led by Dr. Krista Lanctôt, senior scientist and Bernick Chair in Geriatric Psychopharmacology at Sunnybrook Research Institute and the University of Toronto. The trial is supported with funding from the Weston Family Foundation.
Alzheimer’s disease poses a significant health challenge globally, with millions of individuals affected and limited treatment options available. Recognizing the urgent need for more effective therapies, PBG has developed a novel cannabinoid-based drug to target symptoms of Alzheimer’s disease, offering hope for improved patient outcomes and quality of life. “We are pleased to collaborate with PBG on this trial for the treatment of agitation, a common and impactful symptom of Alzheimer’s disease,” said Dr. Krista Lanctôt, study investigator.
“We are excited to announce the commencement of this clinical trial. It marks another significant step forward in our mission to bring meaningful therapies to patients grappling with neurodegenerative disease.” said Dr. Jacqueline Shan, founder, and Chief Executive Officer of PBG BioPharma Inc.
PBG remains dedicated to adhering to the highest standards of product quality, and regulatory requirements. Together with its research collaborations, the company is committed to working closely with regulatory authorities, healthcare professionals, and patient advocacy groups to advance the development of potential new therapies.
About PBG BioPharma Inc.
PBG BioPharma Inc. is a vertically integrated biopharmaceutical company focusing on the research, development, and manufacturing of biopharmaceuticals and nutraceuticals. The company takes a pharmaceutical approach to its product development, testing and manufacturing process for premium quality, pharmaceutical grade ingredients and formulations. PBG has constructed a state-of-the-art, GMP standard biopharmaceutical production and lab facility and is currently conducting research and therapeutic development in the areas of mental health disorders, neuropathic pain and broad-spectrum anti-viral.
About Sunnybrook Research Institute
Sunnybrook Research Institute (SRI) is the research arm of Sunnybrook Health Sciences Centre, an internationally recognized academic health sciences centre fully affiliated with the University of Toronto. With well-established programs in basic and applied sciences which span across three scientific platforms and ten clinical programs, SRI is developing innovations in care for the more than 1.1 million patient visits the hospital provides annually.
